IGNYTA (RXDX) Reports RXDX-101 Phase I Presentation at the 2014 ESMO
Tweet Send to a Friend
Ignyta, Inc. (Nasdaq: RXDX) today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
